Extended Data Fig. 8: ERCC6L2 Is Downregulated in Multiple Cancer Types.
From: Phase separation of ERCC6L2–CtIP regulates the extent of DNA end resection
a–w. ERCC6L2 mRNA expression in normal tissues and human cancer samples from TCGA database. Data are presented as mean ± SD, statistical analysis was performed using the two-tailed Mann-Whitney test. COAD: Colon Cancer, n = 41 normal, 469 tumour; READ: Rectal Cancer, n = 10 normal, 166 tumour; BLCA: Bladder Cancer, n = 19 normal, 411 tumour; BRCA: Breast Cancer, n = 113 normal, 1097 tumour; GBM: Glioblastoma, n = 5 normal, 155 tumour; KIRC: Kidney Clear Cell Carcinoma, n = 72 normal, 534 tumour; KIRP: Kidney Papillary Cell Carcinoma, n = 32 normal, 288 tumour; LUSC: Lung Squamous Cell Carcinoma, n = 49 normal, 501 tumour; PRAD: Prostate Cancer, n = 52 normal, 498 tumour; THCA: Thyroid Cancer, n = 58 normal, 502 tumour; UCEC: Endometrioid Cancer, n = 35 normal, 547 tumour; CHOL: Bile Duct Cancer, n = 9 normal, 36 tumour; STAD: Stomach Cancer, n = 259 normal, 375 tumour; CESC: Cervical Cancer, n = 3 normal, 304 tumour; KICH: Kidney Chromophobe, n = 24 normal, 65 tumour; ESCA: Esophageal Cancer, n = 12 normal, 161 tumour; HNSC: Head and Neck Cancer, n = 44 normal, 500 tumour; LIHC: Liver Cancer, n = 50 normal, 371 tumour; LUAD: Lung Adenocarcinoma, n = 59 normal, 524 tumour; PAAD: Pancreatic Cancer, n = 4 normal, 177 tumour; PCPG: Pheochromocytoma and Paraganglioma, n = 3 normal, 178 tumour; SARC: Sarcoma, n = 2 normal, 259 tumour; THYM: Thymoma, n = 2 normal, 119 tumour.
